drugset / Trial / NCT02503033
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies
Timeline
- Start
- 2015-11
- Primary completion
- 2020-12
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sovleplenib | Small molecule | 100 mg | Oral |
| Subject | Sovleplenib | Small molecule | 200 mg | Oral |
| Subject | Sovleplenib | Small molecule | 300 mg | Oral |
| Subject | Sovleplenib | Small molecule | 400 mg | Oral |
| Subject | Sovleplenib | Small molecule | 600 mg | Oral |
| Subject | Sovleplenib | Small molecule | 800 mg | Oral |
| Subject | Sovleplenib | Small molecule | 1000 mg | Oral |